ArticleBritish journal of cancer2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Johanna C Bendell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
73 papers cite itlatest 60 shown
this paperpooled ittrialcites it